Preclinical Research to Clinical Practice: A Review of Phytochemicals in Cancer Treatment
Keywords:
Anticancer, Clinical, Medicinal Plants, Phytochemicals, PreclinicalAbstract
Cancer is a serious health issue that remains a top cause of mortality across the globe. Anticancer medications have been developed as we have understood the molecular mechanism that leads to cancer genesis has grown. Chemically produced medications, on the other hand, have had little impact on overall survival rates during the last several decades. As a result, to improve the efficacy of conventional therapies of cancer, new approaches and revolutionary chemoprevention drugs are necessary. Phytochemicals are those molecules that occur naturally in plants, are important resources for developing new medicines and may also be used to treat cancer. Only a few example include taxol analogues, vinca alkaloids such as vinblastine vincristine and, and podophyllotoxin analogues. These phytochemical generally work by interfering with molecular pathways connected to cancer formation and progress. Some of the distinct approaches include increased antioxidants status, carcinogen inactivation, reducing its rapid growth, promotion of cell cycle arrest and death, and immune system regulation. The main goal of this study is to summarise what we now know about natural product active chemicals, including their pharmacology and molecular or particular targets. The most recent advancements and limitations in the development of phytochemical-based anticancer therapies are also discussed. The author wants to boost phytochemicals research not just for its scientific worth, but also for its medicine development potential. As a result, anticancer phytochemicals that have been studied in preclinical and clinical settings have gotten a lot of attention.
Downloads
References
L. S. Adams, S. Phung, N. Yee, N. P. Seeram, L. Li, and S. Chen, “Blueberry phytochemicals inhibit growth and metastatic potential of MDA-MB-231 breast cancer cells through modulation of the phosphatidylinositol 3-kinase pathway,” Cancer Res., 2010, doi: 10.1158/0008- 5472.CAN-09-3565.
J. J. Alumkal et al., “A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer,” Invest. New Drugs, 2015, doi: 10.1007/s10637- 014-0189-z.
D. Aras, O. Cinar, Z. Cakar, S. Ozkavukcu, and A. Can, “Can dicoumarol be used as a gonad-safe anticancer agent: An in vitro and in vivo experimental study,” Mol. Hum. Reprod., 2015, doi: 10.1093/molehr/gav065.
S. Banerjee, C. Bueso-Ramos, and B. B. Aggarwal, “Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: Role of nuclear factor-κB, cyclooxygenase 2, and matrix metalloprotease 9,” Cancer Res., 2002.
M. Bayet-Robert et al., “Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer,” Cancer Biol. Ther., 2010, doi: 10.4161/cbt.9.1.10392.
F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA. Cancer J. Clin., 2018, doi: 10.3322/caac.21492.
S. Bhattacharya et al., “Apigenin loaded nanoparticle delayed development of hepatocellular carcinoma in rats,” Nanomedicine Nanotechnology, Biol. Med., 2018, doi: 10.1016/j.nano.2018.05.011.
J. J. De La Chapa, P. K. Singha, D. R. Lee, and C. B. Gonzales, “Thymol inhibits oral squamous cell carcinoma growth via mitochondria-mediated apoptosis,” J. Oral Pathol. Med., 2018, doi: 10.1111/jop.12735.
R. M. T. de Lima et al., “Protective and therapeutic potential of ginger (Zingiber officinale) extract and [6]- gingerol in cancer: A comprehensive review,” Phytotherapy Research. 2018, doi: 10.1002/ptr.6134.
G. Tan, C. Gyllenhaal, and D. Soejarto, “Biodiversity as a Source of Anticancer Drugs,” Curr. Drug Targets, 2006, doi: 10.2174/138945006776054942.
